急性肝衰竭病情严重程度评估

doi:10.3969/j.issn.1672-5069.2017.01.006

实用肝脏病杂志 ›› 2017, Vol. 20 ›› Issue (1): 17-20.doi: 10.3969/j.issn.1672-5069.2017.01.006

急性肝衰竭病情严重程度评估

李爽, 陈煜

100069 北京市首都医科大学附属北京佑安医院

收稿日期:2016-11-09 出版日期:2017-01-20 发布日期:2017-02-10
通讯作者: 陈煜,北京佑安医院人工肝中心主任,主任医师,教授,博士研究生导师。中华医学会肝病学分会工作秘书及青年委员会副主任委员、重肝及人工肝学组副组长; 北京医学会肝病学分会委员、肝衰竭及人工肝学组副组长;全国重型肝病及人工肝血液净化攻关协作组副组长;北京市科技新星,北京市卫生局“十百千”卫生百名人才,北京市卫生系统高层次卫生技术人才,北京市优秀人才,北京医院协会医疗管理科学专业委员会委员,2015年度首都十大杰出青年医师。E-mail:chybeyond@163.com

Severity evaluation of acute liver failure

Li Shuang, Chen Yu. You'an

Hospital,Capital Medical University,Beijing 100069

Received:2016-11-09 Online:2017-01-20 Published:2017-02-10

摘要/Abstract

关键词: 急性肝衰竭, 预后, 评估

Key words: Acute liver failure, Prognosis, Prediction

李爽, 陈煜. 急性肝衰竭病情严重程度评估[J]. 实用肝脏病杂志, 2017, 20(1): 17-20.

Li Shuang, Chen Yu. You'an.. Severity evaluation of acute liver failure[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(1): 17-20.

[1] 中华医学会感染病学分会肝衰竭与人工肝学组. 肝衰竭诊治指南（2012年版）. 实用肝脏病杂志,2013,7（3）:210-216.
[2] Bernal W,Wendon J. Acute liver failure. New Engl J Med, 2014,370（12）:1170-1171.
[3] Polson J,Lee WM,Disease AAFO. AASLD position paper:the management of acute liver failure:update 2011. Nat Guideline Clearinghouse,2012,65（4）:1433-1441.
[4] Shalimar A,Acharya SK. Management in acute liver failure. J Clin Experiment Hepatol,2015,5（Suppl 1）:104-115.
[5] Lee WM. Acute liver failure. Sem Resp Crit Care Med,2012,33（1）:123-125.
[6] 聂青和. 肝衰竭实验室检测的临床价值及新指标评价. 临床肝胆病杂志,2013,29（9）:666-669.
[7] Wlodzimirow KA,Eslami S,Abu-Hanna A,et al. A systematic review on prognostic indicators of acute liver failure and their predictive value for poor outcome. Bri J Med Med Res,2014,4（4）:2796-2852.
[8] OGrady J. Timing and benefit of liver transplantation in acute liver failure. J Hepatol,2014,60（3）:663-670.
[9] Munoz S J,Stravitz R T,Gabriel D A. Coagulopathy of acute liver failure. Clin Liver Dis,2009,13（1）:95-107.
[10] Merle U,Sieg O,Stremmel W,et al. Sensitivity and specificity of plasma disappearance rate of indocyanine green as a prognostic indicator in acute liver failure. Bmc Gastroenterol,2009,9（1）:1-7.
[11] Ren ZXYZS. Indocyanine green retention test avoiding liver failure after hepatectomy for hepatolithiasis. Hepatogastroenterolog,2012,59（115）:782-784.
[12] Feng H L,Li Q,Wang L,et al. Indocyanine green clearance test combined with MELD score in predicting the short-term prognosis of patients with acute liver failure. Hepatobiliary Pancreat Dis Int,2014,13（3）:271-275.
[13] Rolando N,Wade J,Davalos M,et al. The systemic inflammatory response syndrome in acute liver failure. Hepatology,2000,32（4）:734-739.
[14] Kamath P S,Heimbach J,Wiesner R H. Acute liver failure prognostic scores:Is good enough good enough. Clin Gastroenterol Hepatol,2016,14（4）:621-623.
[15] Stravitz R T,Ellerbe C,Durkalski V,et al. Thrombocytopenia is associated with multi-organ system failure in patients with acute liver failure. Clin Gastroenterol Hepatol,2015,14（4）:613-620.
[16] Rule J A,Hynan L S,Attar N,et al. Procalcitonin identifies cell injury,Not bacterial infection in acute liver failure. Plos One,2015,10（9）:12073.
[17] Antoniades C,Triantafyllou E,Gadhok R,et al. 1013 CD163 is a mechanistic biomarker in acute liver failure reflectiong a macrophage activation like syndrome. J Hepatol,2013,58,（Suppl1）:S417.
[18] MLler HJ,Gr Nbaek H,Schi Dt FV,et al. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J Hepatol,2007,47（5）:671-676.
[19] Takikawa Y,Suzuki K. Is AFP a new reliable marker of liver regeneration in acute hepatic failure. J Gastroenterol,2002,37（8）:681-682.
[20] Schiodt FV,Ostapowicz G,Murray N,et al. Alpha-fetoprotein and prognosis in acute liver failure. Liver Transplant,2006,12（12）:1776-1781.
[21] Karvellas CJ,Fix OK,Battenhouse H,et al. Outcomes and complications of intracranial pressure monitoring in acute liver failure:a retrospective cohort study. Crit Care Med,2014,42（5）:1157-1167.
[22] Bernal W,Hyyrylainen A,Gera A,et al. Lessons from look-back in acute liver failure A single centre experience of 3300 patients. J Hepatol,2013,59（1）:74-80.
[23] Yamagishi Y,Saito H,Ebinuma H,et al. A new prognostic formula for adult acute liver failure using computer tomography-derived hepatic volumetric analysis. J Gastroenterol, 2009,44（6）:615-623.
[24] Romero M,Palmer SL,Kahn JA,et al. Imaging appearance in acute liver failure:Correlation with clinical and pathology findings. Dig Dis Sci,2014,59（8）:1987-1995.
[25] Ashish Singhal SVKS. Liver histology as predictor of outcome in patients with acute liver failure. Transplant Int,2012,25（6）:658-662.
[26] Mcphail MJW,Wendon JA,Bernal W. Meta-analysis of performance of Kings’s College Hospital Criteria in prediction of outcome in non-paracetamol-induced acute liver failure. J Hepatol,2010,53（3）:492-499.
[27] Craig D G N,Ford A C,Hayes P C,et al. Systematic review: prognostic tests of paracetamol-induced acute liver failure. Aliment Pharmacol Therapeut,2010,31（10）:1064-1076.
[28] Bailey B,Amre D K,Gaudreault P. Fulminant hepatic failure secondary to acetaminophen poisoning:a systematic review and meta-analysis of prognostic criteria determining the need for liver transplantation. Crit Care Med, 2003,31（1）:299-305.

急性肝衰竭病情严重程度评估

Severity evaluation of acute liver failure

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	武丹, 马向鹰. 非酒精性脂肪性肝病肝硬化患者胰岛素抵抗水平与颈动脉硬化程度和左心室功能研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 876-879.
[2]	朱玉成, 闫家微, 孙景坤, 张秋月. 慢加急性肝衰竭患者血清二胺氧化酶水平及其临床意义探讨*[J]. 实用肝脏病杂志, 2019, 22(5): 672-675.
[3]	巴正武, 栗海龙, 杨慧. 能谱CT成像定量评估Budd-Chiari综合征患者TIPS术治疗前后肝功能状态临床价值研究*[J]. 实用肝脏病杂志, 2019, 22(5): 680-683.
[4]	张璇, 唐小云, 唐春银, 石学魁, 王惠琦, 张晓东, 沈海萍, 杨春辉. 中药方剂赤白汤对D-氨基半乳糖诱导的急性肝衰竭小鼠肠道菌群的影响研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 478-481.
[5]	庄太平, 尹杨艳, 谢蔓芳, 冯乃超, 陈彩华. 人巨细胞病毒感染与肝炎综合征婴儿临床特点比较^*[J]. 实用肝脏病杂志, 2019, 22(4): 514-517.
[6]	王媛, 党盼玉, 王伟. 血浆置换联合连续性血浆透析滤过治疗慢加急性肝衰竭患者临床疗效及其对血浆细胞因子水平的影响[J]. 实用肝脏病杂志, 2019, 22(4): 541-544.
[7]	彭思璐, 刘冰, 孙宏, 林剑, 潘志颖, 邓存良. HBV相关慢加急性肝衰竭患者预后及其影响因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 545-548.
[8]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[9]	高朋彬,赵晓彦,秦浩,吴凤影,钟海振,王琳,贾慧娜,李树娟. 戊型肝炎肝衰竭死亡原因分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 220-223.
[10]	王虎明,樊东升,徐杰,刘险峰,周宁,丽敏,包娜娜. 肝细胞癌患者癌组织miRNA-30c水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 248-251.
[11]	张小舟,帅领,王庆大,杨楠. 接受TACE治疗的肝细胞癌患者血清miR-335水平变化及其对预后判断的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 268-271.
[12]	谢晓（综述）,陆伦根（审校）. 无创诊断和评估非酒精性脂肪性肝炎研究进展^*[J]. 实用肝脏病杂志, 2019, 22(2): 301-306.
[13]	陈海鸥, 刘适. 慢加急性乙型肝炎肝衰竭患者血清IL-10和GP73水平检测及其临床意义[J]. 实用肝脏病杂志, 2019, 22(1): 73-76.
[14]	马德渊, 马元凤, 张殿隆, 李山林. HBV相关慢加急性肝衰竭患者血清角蛋白18水平及其与患者预后的关系探讨^*[J]. 实用肝脏病杂志, 2019, 22(1): 77-80.
[15]	闫焕杰, 张淑芹, 赵文静. 自体骨髓干细胞移植治疗慢加急性乙型肝炎肝衰竭患者疗效初步研究[J]. 实用肝脏病杂志, 2019, 22(1): 81-84.